Keep up-to-date with PrECOG by visiting our news page regularly.
PALLAS co-chair Angela DeMichele receives the 2023 Gianni Bonadonna Breast Cancer Award Researchers with PrECOG, LLC, are presenting updates and new data at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June. Below, please find the essential information for the presentations, […]
In-depth molecular analyses of responding tumors provide insights into patient selection methods for this novel chemo-immunotherapy regimen, which is currently being evaluated in the DREAM3R phase 3 trial, open to patients in the US, Australia, and New Zealand Philadelphia, November 8, 2021—The PrE0505 phase 2 clinical trial results are published in the November 8 issue […]
After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial For Immediate Release March 17, 2021 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia—The DREAM3R phase three clinical trial is […]
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence For Immediate Release May 29, 2020 Vienna, Brussels, Chicago, Philadelphia, Neu-Isenburg/Frankfurt, Pittsburgh—The Austrian Breast & Colorectal Cancer Study Group (ABCSG), Alliance Foundation Trials (AFT), the Breast International Group (BIG), PrECOG, […]
Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination should advance to a randomized phase 3 study For Immediate Release May 20, 2020 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia, PA—PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two […]